Diabetes

  • FDA advisory committee supports new CV liraglutide indication

    on June 22nd, 2017
    A Food and Drug Administration advisory committee voted 17-2 in support of a supplemental new drug application for liraglutide (Victoza) injections to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. Novo Nordisk, the maker[...]
  • SPRINT: Intensive BP control cut cardiovascular risk in patients with prediabetes

    on June 21st, 2017
    AT THE ADA ANNUAL SCIENTIFIC SESSIONS SAN DIEGO (FRONTLINE MEDICAL NEWS) – Treating systolic hypertension to a target of 120 mm Hg instead of 140 mm Hg significantly reduced the rate of cardiovascular events in high-risk patients with prediabetes, according to a post-hoc analysis of the multicente[...]
  • DURATION-8: Exenatide/dapagliflozin efficacy holds up at 1 year

    on June 21st, 2017
    AT THE ADA ANNUAL SCIENTIFIC SESSIONS SAN DIEGO (FRONTLINE MEDICAL NEWS) – A year of treatment with once-weekly exenatide and once-daily dapagliflozin significantly outperformed either therapy alone for patients whose type 2 diabetes was uncontrolled on metformin, investigators reported at the ann[...]
  • In Sweden, very few osteoporotic fractures prompt treatment within 12 months

    on June 21st, 2017
    AT THE EULAR 2017 CONGRESS MADRID (FRONTLINE MEDICAL NEWS) – In Sweden, less than 7% of those who experience an osteoporotic fracture receive osteoporosis treatment within the first year, when the risk of a second fracture is the highest. Women are more likely than are men to get a prescription, b[...]
  • USPSTF recommends screening children, adolescents for obesity

    on June 20th, 2017
    FROM JAMA Children and adolescents aged 6 years and older should be screened for obesity and referred to comprehensive, intensive behavioral interventions with at least 26 hours of intervention contact, according to a U.S. Preventive Services Task Force Recommendation Statement that was published on[...]
  • Consistent weight benefits seen in empagliflozin use

    on June 14th, 2017
    AT THE ADA ANNUAL SCIENTIFIC SESSIONS SAN DIEGO (FRONTLINE MEDICAL NEWS) – In a follow-up to the blockbuster trial results linking the type 2 diabetes drug empagliflozin (Jardiance) to a dramatically lower risk of cardiac death, researchers report that the drug improved weight-related measures in [...]
  • Rural patients less likely to have bariatric surgery

    on June 14th, 2017
    FROM SURGERY FOR OBESITY AND RELATED DISEASES Obese patients living in rural areas of West Virginia were substantially less likely than were their urban and suburban counterparts to have bariatric surgery, according to findings from a study comparing outcomes in two patient groups. This discrepancy [...]
  • CANVAS: Canagliflozin cuts cardiovascular events, doubles risk of amputations

    on June 14th, 2017
    AT THE ADA ANNUAL SCIENTIFIC SESSIONS SAN DIEGO (FRONTLINE MEDICAL NEWS) – Oral, once-daily treatment with canagliflozin significantly reduced the risk of cardiovascular events, compared with placebo, among more than 10,000 patients with type 2 diabetes at high risk of cardiovascular disease. Afte[...]
  • Identifying type 1 diabetes drivers at risk of mishaps

    on June 14th, 2017
    FROM DIABETES CARE A risk assessment score could help identify individuals with type 1 diabetes who are at higher risk of driving mishaps and who may benefit from interventions to reduce their risk, a new study suggests. Writing in the June edition of Diabetes Care, Daniel J. Cox, MD , of the Univer[...]
  • DEVOTE: Degludec and glargine had similar risk with less severe hypoglycemia

    on June 14th, 2017
    AT THE ADA ANNUAL SCIENTIFIC SESSIONS SAN DIEGO (FRONTLINE MEDICAL NEWS) – For patients with type 2 diabetes at high risk of cardiovascular disease, the ultra–long-acting, once-daily basal insulin degludec produced a similar risk of major adverse cardiovascular events as glargine with a signific[...]
  • Providers buck lipid recommendations in high-risk diabetes

    on June 13th, 2017
    AT THE ADA ANNUAL SCIENTIFIC SESSIONS SAN DIEGO (FRONTLINE MEDICAL NEWS) – In the 3 months before their atherosclerotic cardiovascular event, 40% of high-risk patients with diabetes received no prescription for lipid-lowering therapy, researchers reported at the annual scientific sessions of the A[...]
  • REMOVAL: Metformin may reduce cardiac risk in type 1 diabetes but doesn’t improve glucose control

    on June 12th, 2017
    AT THE ADA ANNUAL SCIENTIFIC SESSIONS SAN DIEGO (FRONTLINE MEDICAL NEWS) – Findings from the landmark 3-year REMOVAL trial find that metformin could hold potential as a tool to reduce cardiovascular disease (CVD) risk in patients with type 1 diabetes. But – in a challenge to current British and [...]
  • Routine blood glucose monitoring does not improve control or QOL

    on June 12th, 2017
    FROM JAMA INTERNAL MEDICINE Self-monitoring of blood glucose in patients with non–insulin-treated type 2 diabetes mellitus (T2DM) does not appear to make any difference to blood glucose control or quality of life, a new study has found. The researchers report the results of the Monitor Trial in wh[...]
Back to top